| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Non-Recombinant Monoclonal | NB600-1159SS | |||
| Azide and BSA Free | NBP2-33250 | |||
| Non-Recombinant Monoclonal | NB600-1159 | |||
| BSA Free | NBP3-07012SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24737SS | |||
| Azide and BSA Free | NBP2-33259 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-302SS | |||
| Azide and BSA Free | NBP2-80675 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-103SS | |||
| Azide and BSA Free | NBP2-80898 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76769SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-56893SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1992SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-336SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-306SS | |||
| Azide and BSA Free | NBP2-80586 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56098SS | |||
![Western Blot: Noxa Antibody (114C307.1R) [NBP3-07012] - Doc counteracts the ABT-737-mediated increase in Mcl-1 protein. Western blot showing treatment of LNCaP and PC3 cells with 1 uM ABT-737. In LNCaP and PC3, there are few difference in Noxa. Image collected and cropped by CiteAb from the following publication (//peerj.com/articles/144), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Western-Blot-NBP3-07012-img0003.jpg "Western Blot: Noxa Antibody (114C307.1R) [NBP3-07012] - Doc counteracts the ABT-737-mediated increase in Mcl-1 protein. Western blot showing treatment of LNCaP and PC3 cells with 1 uM ABT-737. In LNCaP and PC3, there are few difference in Noxa. Image collected and cropped by CiteAb from the following publication (//peerj.com/articles/144), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: Noxa Antibody (114C307.1R) [NBP3-07012] - ICC/IF analysis using the azide-free version of NB600-1159 at 1:10. HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Image objective 40X.](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Immunocytochemistry-Immunofluorescence-NBP3-07012-img0004.jpg)
![Flow Cytometry: Noxa Antibody (114C307.1R) [NBP3-07012] - An intracellular stain was performed on Ntera2 cells with Noxa Antibody [114C307.1R] NBP3-07012 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Flow-Cytometry-NBP3-07012-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Noxa Antibody (114C307.1R) [NBP3-07012] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-Noxa Antibody (114C307.1R) NBP3-07012 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Noxa-Antibody-114C307-1R-Immunocytochemistry-Immunofluorescence-NBP3-07012-img0001.jpg)
![Immunohistochemistry-Paraffin: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Immunohistochemical analysis of bouin-fixed, paraffin-embedded chronic lymphocytic leukemia (CLL) xenograft stained with Noxa antibody (1:2000), peroxidase-conjugate and DAB chromogen. Staining for 2 hr at RT was used.](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-1772024104467.jpg)
![Western Blot: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Detection by Western blot in RL-7 cells (a follicular lymphoma).](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-1772024959411.jpg)
![Flow Cytometry: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Flow cytometry after an intracellular stain was performed on MCF7 cells with Noxa [114C307.1] antibody NB600-1159AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were directly conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-1772024959421.jpg)
![Flow Cytometry: Noxa Antibody (114C307.1R) - BSA Free [NBP3-07012] - Flow cytometry after an intracellular stain was performed on HeLa cells with Noxa [114C307.1] antibody NB600-1159AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were directly conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/nbp3-07012_mouse-monoclonal-noxa-antibody-114c307-1r-17720249362613.jpg)
![Western Blot: p73 Antibody (5B429) [NBP2-24737] - Consequences of DHX9 knockdown on protein levels of p53 targets in HCT116 p53+/+ and p53-/- cells. Western blot analysis of p53 transcriptional targets in HCT116 p53+/+ and p53-/- cells. Cells were harvested 6 days post-transduction and extracts were fractionated on 8% SDS-PAGE gels. All probings were performed on the same blot. Actin and eEF2 are used as loading controls. Quantitation of intensity levels of the proteins in the shDHX9 samples relative to the shFLuc. 1309 samples are indicated beneath each band. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/article/15889/text/), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p73-Antibody-5B429-Western-Blot-NBP2-24737-img0009.jpg "Western Blot: p73 Antibody (5B429) [NBP2-24737] - Consequences of DHX9 knockdown on protein levels of p53 targets in HCT116 p53+/+ and p53-/- cells. Western blot analysis of p53 transcriptional targets in HCT116 p53+/+ and p53-/- cells. Cells were harvested 6 days post-transduction and extracts were fractionated on 8% SDS-PAGE gels. All probings were performed on the same blot. Actin and eEF2 are used as loading controls. Quantitation of intensity levels of the proteins in the shDHX9 samples relative to the shFLuc. 1309 samples are indicated beneath each band. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/article/15889/text/), licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: p73 Antibody (5B429) [NBP2-24737] - p73 was detected in immersion fixed Hela human cell line using p73 [5B429] Monoclonal Antibody (Catalog # NBP2-24737) at 3 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Staining was observed in the cytoplasm and in the nuclei.](http://images.novusbio.com/fullsize/p73-Antibody-5B429-Immunocytochemistry-Immunofluorescence-NBP2-24737-img0008.jpg)
![Immunohistochemistry-Paraffin: p73 Antibody (5B429) [NBP2-24737] - FFPE breast cancer probed with p73 antibody at 5 ug/ml. Human tissue was used for this test. Staining of tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/p73-Antibody-5B429-Immunohistochemistry-Paraffin-NBP2-24737-img0004.jpg)
![Flow Cytometry: p73 Antibody (5B429) [NBP2-24737] - Detection of p73 in Human HeLa Cell Line. Human HeLa cell line was stained with Mouse Anti- p73 Monoclonal Antibody (Catalog # NBP2-24737, filled histogram), or Mouse IgG1 isotype control (Catalog # MAB002, open histogram) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/p73-Antibody-5B429-Flow-Cytometry-NBP2-24737-img0007.jpg)
![Western Blot: p73 Antibody (5B429) [NBP2-24737] - Analysis of p73 in A) transfected cell lysate and B) HeLa cell lysate at 2 ug/ml.](http://images.novusbio.com/fullsize/p73-Antibody-5B429-Western-Blot-NBP2-24737-img0003.jpg)
![Flow (Intracellular): p73 Antibody (5B429) [NBP2-24737] - An intracellular stain was performed on HeLa cells with pan p73 (5B429) antibody NBP2-24737 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/p73-Antibody-5B429-Flow-Intracellular-NBP2-24737-img0006.jpg)
![Simple Western: p73 Antibody (5B429) [NBP2-24737] - Lane view shows a specific band for p73 in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230kDa separation system. * Non-specific interaction with the 230 kDa Simple Western standard may be seen with this antibody.](http://images.novusbio.com/fullsize/p73-Antibody-5B429-Simple-Western-NBP2-24737-img0005.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - CtIP is phosphorylated by CDKs at multiple sites. Myc-BRCA1 and/or HA-CtIP WT or indicated mutants were expressed in 293T cells and co-immunoprecipitation was performed. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pgen.1003277) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0022.jpg "Western Blot: c-Myc Antibody (9E10) [NB600-302] - CtIP is phosphorylated by CDKs at multiple sites. Myc-BRCA1 and/or HA-CtIP WT or indicated mutants were expressed in 293T cells and co-immunoprecipitation was performed. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pgen.1003277) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: c-Myc Antibody (9E10) [NB600-302] - c-Myc was detected in immersion fixed paraffin-embedded sections of human breast cancer using anti-human mouse monoclonal antibody (Catalog # NB600-302, clone 9E10) at 1:50 dilution overnight at 4 C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue). Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Immunohistochemistry-Paraffin-NB600-302-img0009.jpg)
![Simple Western: c-Myc Antibody (9E10) [NB600-302] - Simple Western lane view shows a specific band for c-Myc in 0.5 mg/ml of Jurkat lysate. This experiment as performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Simple-Western-NB600-302-img0006.jpg)
![Western Blot: c-Myc Antibody (9E10) - BSA Free [NB600-302] - Western blotting analysis of unsorted (W) and sorted ROSl degrees w(L) and ROShigh(H) cells. Data shown are representative of at least two independent experiments.DyLight 650 conjugated version of this antibody used (NB600-302C). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25857523/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-BSA-Free-Western-Blot-NB600-302-img0026.jpg)
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody (9E10) [NB600-302] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-c-Myc (9E10) at 10 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Immunocytochemistry-Immunofluorescence-NB600-302-img0011.jpg)
![Flow (Intracellular): c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.. Using the PE format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Intracellular-NB600-302-img0024.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - Analysis of c-myc in Jurkat cell lysates using NB600-302.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0005.jpg)
![Western Blot: c-Myc Antibody (9E10) [NB600-302] - Flow cytometric analysis of ROS and the mitochondrial status. Western blotting analysis of unsorted (W) and sorted P1 and P2 cells. Data shown are representative of at least two independent experiments. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/ncomms7750) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Western-Blot-NB600-302-img0025.jpg)
![Flow Cytometry: c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Cytometry-NB600-302-img0014.jpg)
![Flow Cytometry: c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on Jurkat cells with c-Myc Antibody (9E10) NB600-302R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Cytometry-NB600-302-img0019.jpg)
![Flow (Intracellular): c-Myc Antibody (9E10) [NB600-302] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E10) NB600-302F (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to FITC.. Using the FITC format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E10-Flow-Intracellular-NB600-302-img0023.jpg)
![Western Blot: c-Myc Antibody (9E10) - BSA Free [NB600-302] - NLRP2 interacts with SCMC components TLE6, OOEP, FILIA & NLRP5.(A) NLRP2 was overexpressed with myc-tagged OOEP, TLE6, NLRP5 & FILIA in HEK293T cells for 48 hours, immunoprecipitated with anti-NLRP2 or IgG as negative control & immunoblotted with anti-myc. Top panel shows specificity of anti-NLRP2 IP & bottom panel shows that NLRP2 binds to OOEP, TLE6, FILIA & NLRP5. Uncropped, full length western blots have been provided in Supplementary Figure 5. (B) Whole-mount immunofluorescence co-staining with anti-NLRP2 (green) & DAPI (blue) for nuclear staining on Nlrp2+/+ oocytes & embryos at 2-, 4-,16-cell & morula stages revealed a predominantly SCMC-like localization for NLRP2. Scale bars represent 200 μm. (C) Co-staining with anti-TLE6 (green) & DAPI (blue) of paraffin-embedded oocyte sections reveals a typical cortical stain of TLE6 in oocytes of Nlrp2+/+ dams but a more intense & diffuse stain in oocytes of Nlrp2tm1a/tm1a dams. Scale bars represent 10 μm. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/srep44667), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-302_mouse-monoclonal-c-myc-antibody-9e10-310202416163779.jpg)
![Western Blot: c-Myc Antibody [NB600-335] - Detection of c-myc-tagged Protein by Western Blot. Samples: 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibodies: Affinity purified, goat anti-c-myc antibody NB600-335 at 0.04 ug/ml (1:25,000). Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-335-img0006.jpg "Western Blot: c-Myc Antibody [NB600-335] - Detection of c-myc-tagged Protein by Western Blot. Samples: 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibodies: Affinity purified, goat anti-c-myc antibody NB600-335 at 0.04 ug/ml (1:25,000). Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody [NB600-335] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-c-Myc conjugated to Alexa Fluor 488 [NB600-335AF488] at 20 ug/mL for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective. Image using the Alexa Fluor 488 format of this antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Immunocytochemistry-Immunofluorescence-NB600-335-img0007.jpg)
![Western Blot: c-Myc Antibody [NB600-335] - Analysis using the HRP conjugate of NB600-335. Detection of 200, 100, or 50 ng of E. coli whole cell lysate expressing a multi-tag fusion protein. Antibody used at 0.4 ug/mL (1:25,000).](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-335-img0005.jpg)
![Western Blot: p53 Antibody (PAb 240) [NB200-103] - Analysis of p53 in MCF7 and HeLa lystates. Image courtesy of anonymous customer product review.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Western-Blot-NB200-103-img0001.jpg "Western Blot: p53 Antibody (PAb 240) [NB200-103] - Analysis of p53 in MCF7 and HeLa lystates. Image courtesy of anonymous customer product review.")
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - PC12 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-p53 Antibody (PAb 240) NB200-103 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0013.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (PAb 240) [NB200-103] - p53 was detected in immersion fixed paraffin-embedded sections of human prostate cancer using anti-human mouse monoclonal antibody (Catalog # NB200-103) at 1:200 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue). Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunohistochemistry-Paraffin-NB200-103-img0005.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on HeLa cells with p53 Antibody [PAb 240] NB200-103 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-p53 (PAb 240) [NB200-103] at a 1:200 dilution overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-p53 Antibody (PAb 240) NB200-103 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p53 Antibody (PAb 240) [NB200-103] - Neuro2a cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-p53 Antibody (PAb 240) NB200-103 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Immunocytochemistry-Immunofluorescence-NB200-103-img0012.jpg)
![Flow (Intracellular): p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on HeLa cells with p53 (PAb240) NB200-103 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by APC-conjugated anti-mouse IgG secondary antibody F0101B.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Intracellular-NB200-103-img0003.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on HeLa cells with p53 (PAb240) NB200-103AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0006.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on A549 cells with p53 (PAb240) NB200-103AF488 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0007.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on MCF7 cells with p53 [PAb 240] Antibody NB200-103AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0008.jpg)
![Flow Cytometry: p53 Antibody (PAb 240) [NB200-103] - An intracellular stain was performed on Neuro2a cells with p53 Antibody [PAb 240] NB200-103 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/p53-Antibody-PAb-240-Flow-Cytometry-NB200-103-img0009.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Knockdown-Validated-NBP1-76769-img0024.jpg "<b>Genetic Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Validation with PD-L1 siRNA Knockdown. HeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2). Loading: 10 ug of HeLa whole cell lysates per lane. Antibodies: NBP1-76769 (2 ug/mL) and GAPDH (0.02 ug/mL), 1 h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.")
![<b>Independent Antibodies Validation and Genetic Strategies Validation.</b>Western Blot: PD-L1 Antibody [NBP1-76769] - Independent Antibody Validation (IAV) via Protein Expression ProfileLoading: 15 ug of lysates per lane.Antibodies: NBP1-76769 (2 ug/mL), PD-L1 (2 ug/mL), and beta-actin (1 ug/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0023.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA database , HNSCC tissue samples and the HNSCC cells. Immunostaining of PD-L1 obtained from HNSCC tumor cells, immune cells and tumor margin tissues in HNSCC tissue samples (magnification A-200, scale bars 50AI1/4m) : low tumor staining; moderate tumor staining; high tumor staining have been observed. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-Negative-NBP1-76769-img0025.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - PD-L1 expression was evaluated in gastric cancer cells. Levels of PD-L1 protein were assessed in normal human gastric epithelial cells and 8 gastric cancer cell lines by Western blots. Image collected and cropped by Citeab from the following publication (Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res (2019)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: PD-L1 Antibody [NBP1-76769] - Upregulated expression of PD-L1 in cisplatin-resistant cells through IL-6/STAT3. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0027.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - CD274 (PD-L1) expression in the HNSCC patients from the TCGA databas HNSCC cells. CD274 expression with survival and its relation with therapy in the HNSCC patients from the TCGA database. Expression of CD274 gene and PD-L1 protein in the established cisplatin-resistant HNSCC cells and cisplatin sensitive cells by qRT-PCR and WB (F, H): CD274 (PD-L1) expressed in cisplatin resistant cell. Image collected and cropped by Citeab from the following publication (Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1. Cancer Med (2018)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0028.jpg)
![Immunocytochemistry/Immunofluorescence: PD-L1 Antibody [NBP1-76769] - U-251 MG cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP1-76769 at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-76769-img0029.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - An intracellular stain was performed on U-251 MG cells with PD-L1 Antibody NBP1-76769 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0030.jpg)
![Western Blot: PD-L1 Antibody [NBP1-76769] - Expression of CD274 in Human melanoma SK-MEL-28 cell line upon treatment with 200 mM ethanol. Dilution: 1:1,000 in PBS with 5% BSA. Secondary Ab: anti-Rabbit IgG 1:5,000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Western-Blot-NBP1-76769-img0019.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Human tonsil tissue with PD-L1 antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0017.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - Staining of human heart tissue with antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0010.jpg)
![Immunohistochemistry-Paraffin: PD-L1 Antibody [NBP1-76769] - PD-L1/B7-H1 Antibody [NBP1-76769] - PD-L1 in rat heart tissue with at 5 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunohistochemistry-Paraffin-NBP1-76769-img0020.jpg)
![Flow Cytometry: PD-L1 Antibody [NBP1-76769] - B7-H1/PD-L1/CD274 Antibody [NBP1-76769] - Analysis of A-20 cells using B7-H1/PD-L1/CD274 antibody at 0.5 ug/mL. Green: Isotype control. Red : B7-H1/PD-L1/CD274 antibody.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Flow-Cytometry-NBP1-76769-img0018.jpg)
![Immunofluorescence: PD-L1 Antibody [NBP1-76769] - Human Heart cells with PD-L1 antibody at 20 ug/mL.](http://images.novusbio.com/fullsize/PD-L1-Antibody-Immunofluorescence-NBP1-76769-img0009.jpg)
![Dual RNAscope ISH-IHC: PD-L1 Antibody [NBP1-76769] - PDCD1 mRNA (red) and PD-L1 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human lung cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-PDCD1 and PD-L1 antibody at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/PD-L1-Antibody-Dual-RNAscope-ISH-IHC-NBP1-76769-img0031.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS mediated PD-L1 upregulation in FFA-treated LO2 cells. (a) Intracellular ROS in LO2 cells before & after FFA treatment measured by DCFH-DA. (b–d) Expression levels of NOX2 & NOX4 measured using qRT-PCR & western blot. (e) JC-1 probes were used to detect mitochondrial membrane potential. (f–j) Intracellular ROS in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by DCFH-DA, PD-L1 expression determined by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415382415.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241534538.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 expression levels in liver samples & FFA-treated LO2 cells. (a–d) PD-L1 expression & CD8+ T cells in the liver tissues determined by immunohistochemistry. (e) Intracellular lipid accumulation after FFA treatment (0.8 mM) for 24 hour measured by Oil Red staining. (f–i) Expression levels of PD-L1 detected by qRT-PCR, western blot, & immunofluorescence. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175299.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415291978.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Inhibition of NF-kappa B or STAT3 downregulated PD-L1 expression in adi-CM model. a PD-L1 protein levels in HepG2 cells treated with different concentration of NF-kappa B inhibitor, withaferin A (WA). b PD-L1 protein levels in HepG2 cells treated with different concentration of STAT3 inhibitor, BP-1-102. c PD-L1 protein levels in B16-F1 cells incubated with WA. Data are expressed as mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 Vs adi-CM group. ##P < 0.01 & ###P < 0.001 Vs DMSO group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32477009), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415175210.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ROS/ZNF24/PD-L1 pathway activation in NAFLD models. (a) Intracellular ROS in hepatocytes in NAFLD significantly increased. (b) JC-1 probes were used to detect mitochondrial membrane potential. (c & d) NOX4 & ZNF24 expressions were determined by immunohistochemistry. (e & f) ROS/ZNF24/PD-L1 pathway activation examined by western blot. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415284517.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 limits liver injury in NAFLD models. (a & b) Western blot determined the effect of siRNA against PD-L1. (c) After PD-L1 knockdown, mRNA expression levels of markers of T cell activation measured by qRT-PCR. (d & e) Hepatocyte injury was evaluated by the Tunel assay & ALT/AST measurement. (f) Graph illustrating that both ROS/ZNF24 pathway activation & UBE2I-mediated ZNF24 sumoylation suppression induced by FFA promoted PD-L1 expression. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-31020241529331.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - PD-L1 knockdown aggravated the damage of CD8 + T cells to FFA-treated LO2 cells. (a & b) Western blot determined the effect of siRNA against PD-L1. Coculturing of FFA-treated LO2 cells & CD8 + T cells in vitro. (c) mRNA expression levels of markers of T cell activation measured by qRT-PCR, (d) LO2 cell injury was evaluated by LDH assay, (e) AST or ALT in the supernatants measured by commercial assay kits. # represents that CD8 + T cells were incubated separately with LO2 cells, but supernatants were put together. ∗P < 0.05, ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202415304228.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Upregulated expression of PD‐L1 in cisplatin‐resistant cells through IL‐6/STAT3. The cisplatin resistant CAL27cis & Detroit‐562cis cells had increased IL‐6 mRNA & IL‐6 protein production compared to parental cells by qRT‐PCR & ELISA (A, B). CAL27cis & Detroit‐562cis were cultured with IL‐6 (10 ng/mL, human recombinant IL‐6, R&D Systems, Minneapolis, USA) for 48 h (C). An anti‐human IL‐6 polyclonal antibody (R&D Systems, Minneapolis, USA) was used to neutralize the biological activities of IL‐6 (E, F). To inhibit signal transduction, CAL27cis & Detroit‐562cis cells were pre‐incubated for 1 h with STAT3 inhibitor V (Sigma‐Aldrich, Germany, 500 nmol/L), & then incubated with recombinant human IL‐6 (10 ng/mL) for 24 h before analysis. Data are shown as mean ± SD of 3 independent triplicate cultures (A, B, D, E, F, H). *P < .05, **P < .01 & ***P < .001, compared with the results of control without IL‐6 (D), control IgG (E, F) & with IL‐6 alone (H) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175266.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - ZNF24 promoted PD-L1 expression through binding to its promoter in FFA-treated LO2 cells. (a) A schematic of the target sites (wild & mutant) of ZNF24 in the promoter of PD-L1. (b–d) Dual-luciferase reporter assays performed in LO2 cells transfected with WT or MT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression. (e–g) ZNF24 expression after FFA treatment determined by qRT-PCR & western blot. (h & i) ZNF24 expression in LO2 cells pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment, measured by western blot. (j & k) ZNF24 & PD-L1 expression in LO2 cells pretreated with siRNA against ZNF24, followed by FFA treatment detected by western blot. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416165623.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - LfcinB reduced IL‐6‐dependent PD‐L1 expression in cisplatin‐resistant HNSCC cells (A‐C) & inhibited the xenograft growth from CAL27cis & Detroit‐562cis (D, E). The markedly decreased IL‐6 (A) by ELISA & PD‐L1 by WB (B, C) in the acquired cisplatin‐resistant cells were detected. In figure A, C & D, data are shown as mean ± SD of 3 independent triplicate cultures. *P < .05 & **P < .01, compared with the results of control without IL‐6 (A, C). To investigate the effects of LfcinB on in vivo growth of CAL27cis & Detroit‐562cis, we treated nude mice carrying CAL27cis (D) & Detroit‐562cis (E) xenografts with once‐daily injection of 0.75 mg LfcinB (n = 5). Tumor growth of HNSCC xenografts displayed significant reduction after 3 days of LfcinB treatment, compared to control with saline (*P < .05 for LfcinB) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29761938), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175227.jpg)
![Western Blot: PD-L1 Antibody - BSA Free [NBP1-76769] - Identification of ZNF24–UBE2I protein interactions. (a & b) Analysis of protein interactions between ZNF24 & UBE2I using the BioGRID database, further confirmed by Co-IP assays. (c–f) UBE2I expression in LO2 cells treated by FFA or pretreated with siRNA against NOX4, MitoTEMPO (10 μM), or NAC (5 mM) followed by FFA treatment measured by western blot. (g & h) After FFA treatment, Sumo-1: ZNF24 & ZNF24 expression levels detected by western blot. (i & j) After UBE2I overexpression, Sumo-1: ZNF24, ZNF24, PD-L1, & UBE2I expression levels were determined by western blot. (k–m) Dual-luciferase reporter assays performed in LO2 cells transfected with WT plasmid containing ZNF24-binding sites in the PD-L1 promoter using Lipofectamine 2000 after ZNF24 overexpression with or without Sumo-1 overexpression. ∗∗P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35615575), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-76769_rabbit-polyclonal-pd-l1-antibody-310202416175269.jpg)
![Western Blot: DDX6 Antibody [NB200-191] - Western blot analysis of LBCs show increased Staufen (STAU1) (NBP1-33202) levels compared with normal controls. DDX6 (NB200-191) levels are unchanged. HD and SCA3 patient (polyQ expanded) FBs were used as additional controls. Four normal and five SCA2 FBs, and two normal and three SCA2 LBCs were used.Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30194296/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/DDX6-Antibody-Western-Blot-NB200-191-img0014.jpg "Western Blot: DDX6 Antibody [NB200-191] - Western blot analysis of LBCs show increased Staufen (STAU1) (NBP1-33202) levels compared with normal controls. DDX6 (NB200-191) levels are unchanged. HD and SCA3 patient (polyQ expanded) FBs were used as additional controls. Four normal and five SCA2 FBs, and two normal and three SCA2 LBCs were used.Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30194296/) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: DDX6 Antibody [NB200-191] - In normal condition, cells were fixed and stained for DDX6, that usually punctuate in process bodies (PBs). Primary Antibody rabbit-anti-DDX6 diluted 1:1000. Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunocytochemistry-Immunofluorescence-NB200-191-img0008.jpg)
![Immunohistochemistry-Paraffin: DDX6 Antibody [NB200-191] - Section of human colon carcinoma (left) and mouse renal cell carcinoma(right). Antibody: Affinity purified rabbit anti-DDX6 used at a dilution of 1:200 (1ug/ml). Detection: DAB.](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunohistochemistry-Paraffin-NB200-191-img0013.jpg)
![Immunoprecipitation: DDX6 Antibody [NB200-191] - Detection of human DDX6 by Western Blot and Immunoprecipitation. Samples: Whole cell lysate (15 and 50 ug) from HeLa cells. Antibodies: Affinity purified rabbit anti-DDX6 antibody NB200-191 used at 0.04 ug/ml for WB (A and B) and at 3 ug/mg lysate for IP. DDX6 was also immunoprecipitated using rabbit anti-DDX6 antibody NB200-192, but not with 'DDX6 Ab', which is to another epitope from DDX6. Normal rabbit IgG was used as a negative control. Detection: Chemiluminescence with an exposure time of 1 second (A & B).](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunoprecipitation-NB200-191-img0012.jpg)
![Western Blot: DDX6 Antibody [NB200-191] - Staufen1 protein but not mRNA steady-state levels are increased in neurodegenerative disease cells & tissues. Western blot analysis of SCA2- FBs (a) & LBCs (b) show increased STAU1 levels compared with normal controls. DDX6 levels are unchanged. HD & SCA3 patient (polyQ expanded) FBs were used as additional controls. Four normal & five SCA2 FBs, & two normal & three SCA2 LBCs were used. c, d Western blot analyses of ATXN2Q127 (c) & BAC-Q72 (d) mouse cerebellar extracts (24 weeks of age) showing increased Stau1 levels compared with wild-type or BAC-Q22 controls (n = 2–3 animals per group). e Western blot of FB extracts from an ALS patient with the TDP-43G298S mutation show increased STAU1 levels. beta -Actin was used as loading control & representative blots of three independent experiments are shown. f–hSTAU1 RNA levels are unaltered in SCA2 & ALS cells & SCA2 mice. qRT-PCR analyses of STAU1 mRNA in SCA2 FBs & ALS FB with TDP-43G298S mutation (f) or SCA2 LBCs (g). h qRT-PCR analyses of cerebellar RNAs from ATXN2Q127 & BAC-Q72 mice compared to wild-type littermates (24 weeks of age; n = animals per group). Gene expression levels were normalized to Actb Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30194296), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-191_rabbit-polyclonal-ddx6-antibody-310202416212368.jpg)
![Western Blot: ATG9A Antibody [NB110-56893] - Detection of ATG9A protein in HEK293 lysates using NB110-56893. (1) siRNA ATG9A knockdown and (2) wildtype ATG9A.](http://images.novusbio.com/fullsize/ATG9A-Antibody-Western-Blot-NB110-56893-img0006.jpg "<b>Genetic Strategies Validation. </b>Western Blot: ATG9A Antibody [NB110-56893] - Detection of ATG9A protein in HEK293 lysates using NB110-56893. (1) siRNA ATG9A knockdown and (2) wildtype ATG9A.")
![<b>Genetic Strategies Validation. </b>Western Blot: ATG9A Antibody [NB110-56893] - After stimulation with the NOD1 ligand, macrophages increased their expression of autophagy proteins Atg9, LC3 and IRGM. Alveolar macrophages (AMs), monocyte-derived macrophages (MDMs) and monocytes (MNs) were incubated in the presence of 5 ug/ml of Tri-DAP for 24 h. Cells were pre-incubated with Rip2/p38 inhibitor SB203580 (SB) for 30 min prior to Tri-DAP stimulation to block NOD1-mediated responses, as indicated. Atg9 and LC3 proteins were measured in the cytosolic fractions by western blot analysis. Image collected and cropped by CiteAb from the following publication (//bmcpulmmed.biomedcentral.com/articles/10.1186/1471-2466-14-152), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/ATG9A-Antibody-Western-Blot-NB110-56893-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: ATG9A Antibody [NB110-56893] - Neuro2a cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-ATG9A at 2 ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/ATG9A-Antibody-Immunocytochemistry-Immunofluorescence-NB110-56893-img0008.jpg)
![Immunohistochemistry: ATG9A Antibody [NB110-56893] - Staining in mouse intestine.](http://images.novusbio.com/fullsize/ATG9A-Antibody-Immunohistochemistry-NB110-56893-img0005.jpg)
![Flow Cytometry: ATG9A Antibody [NB110-56893] - An intracellular stain was performed on Hela Cells with NB110-56893 and a matched isotype control. Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG APC-conjugated Secondary Antibody (R&D Systems, F0111).](http://images.novusbio.com/fullsize/ATG9A-Antibody-Flow-Cytometry-NB110-56893-img0007.jpg)
![Western Blot: ATG9A Antibody - BSA Free [NB110-56893] - The effect of chloroquine, spautin-1 & MG132 on ATG protein levels in A549 cells. (A) A549 cells were treated with 50 μM chloroquine, 10 μM spautin-1 or 5 μM MG132 in the presence or absence of 250 pM TGF beta 1 for 24 h. Cells were lysed & subjected to SDS-PAGE & immunoblotting anti-ATG3, anti-ATG5, anti-ATG7, anti-ATG9, anti-ATG12, anti-ATG12-ATG5 complex, anti-ATG16L1, anti-BECN1, anti-ULK1, anti-LC3B, anti-P-Smad2, anti-Smad2 & anti-GAPDH (loading control) antibodies. (B) The steady state levels of ATG3, ATG5, ATG7, ATG9, ATG12, ATG12-ATG5, ATG16L1, BECN1, ULK1, & LC3B were quantitated using QuantityOne software & graphed (n=3, mean±s.e.m.). Significance is indicated as *=P<0.05, **P<0.01 & ****=P<0.0001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33168592), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-56893_rabbit-polyclonal-atg9a-antibody-310202415371977.jpg)
![Western Blot: ATG9A Antibody - BSA Free [NB110-56893] - CD133 promoted glucose uptake.A. Levels of glucose uptake in Huh-7con & Huh-7sh133 cells. Mean fluorescence intensity of 2-NBDG uptake was measured by FASC analysis after incubating for 6 h. B. Time course of 2-NBDG uptake in these two cell lines. Statistical significance indicated as *p<0.05; **p<0.01. C. CD133 or empty vector was transfected respectively into LM3 cells. Glucose uptake was measured at the indicated times upon the medium added with 100 µM 2-NBDG. *p<0.05. D. Detection of relative activities of signaling pathways in Huh-7con & Huh-7sh133 cells by Western blotting. con: Huh-7con cells; sh: Huh-7sh133 cells. E. Detection of autophagic genes in Huh-7con & Huh-7sh133 cells by Western blotting. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23437259), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-56893_rabbit-polyclonal-atg9a-antibody-310202415382433.jpg)
![Western Blot: ATG9A Antibody - BSA Free [NB110-56893] - The effect of TGF beta 1 on ATG protein levels & LC3B lipidation in A549 cells. (A) A549 cells were treated with 250 pM TGF beta 1 for 24 h. Cells were lysed & subjected to SDS-PAGE & immunoblotting anti-ATG3, anti-ATG5, anti-ATG7, anti-ATG9, anti-ATG12, anti-ATG12-ATG5 complex, anti-ATG16L1, anti-BECN1, anti-ULK1, anti-LC3B, anti-P-Smad2, anti-Smad2 & anti-GAPDH (loading control) antibodies. (B) The steady state levels of ATG3, ATG5, ATG7, ATG9, ATG12, ATG12-ATG5, ATG16L1, BECN1, ULK1, & LC3B were quantitated using QuantityOne software & graphed (n=3±s.e.m.). Significance is indicated as *=P<0.05, **P<0.01 & ****=P<0.0001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33168592), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-56893_rabbit-polyclonal-atg9a-antibody-310202415384151.jpg)
![Immunohistochemistry: SOD2/Mn-SOD Antibody [NB100-1992] - The effects of a high calcium/phosphate diet, of 1,25(OH)2D3, and of antioxidant supplementation on oxidative stress, DNA damage, and protein expression of oncogenes and tumor suppressive genes in 1alpha(OH)ase -/- mice. Mice from each group were treated as described in Figure 1. Representative micrographs of skin sections stained immunohistochemically for SOD2 and gamma-H2AX. Scale bars represent 50 um. Image collected and cropped by CiteAb from the following publication (//onlinelibrary.wiley.com/doi/abs/10.1111/acel.12951), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SOD2-Mn-SOD-Antibody-Immunohistochemistry-NB100-1992-img0013.jpg "<b>Biological Strategies Validation. </b>Immunohistochemistry: SOD2/Mn-SOD Antibody [NB100-1992] - The effects of a high calcium/phosphate diet, of 1,25(OH)2D3, and of antioxidant supplementation on oxidative stress, DNA damage, and protein expression of oncogenes and tumor suppressive genes in 1alpha(OH)ase -/- mice. Mice from each group were treated as described in Figure 1. Representative micrographs of skin sections stained immunohistochemically for SOD2 and gamma-H2AX. Scale bars represent 50 um. Image collected and cropped by CiteAb from the following publication (//onlinelibrary.wiley.com/doi/abs/10.1111/acel.12951), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: SOD2/Mn-SOD Antibody [NB100-1992] - Analysis using Rabbit Anti-SOD (Mn) Polyclonal Antibody. Tissue: HeLa Cells. Species: Human. Fixation: 2% Formaldehyde for 20 min at RT. Primary Antibody: Rabbit Anti-SOD (Mn) Polyclonal Antibody at 1:120 for 12 hours at 4 degrees C. Secondary Antibody: R-PE Goat Anti-Rabbit (yellow) at 1:200 for 120 min at RT. Counterstain: DAPI (blue) nuclear stain at 1:40000 for 120 min at RT. Localization: Mitochondrion matrix. Magnification: 100x. (A) DAPI (blue) nuclear stain. (B) Anti-SOD (Mn) Antibody. (C) Composite.](http://images.novusbio.com/fullsize/SOD2-Mn-SOD-Antibody-Immunocytochemistry-Immunofluorescence-NB100-1992-img0010.jpg)
![Western Blot: SOD2/Mn-SOD Antibody [NB100-1992] - Western blot analysis of Rat Tissue lysates showing detection of SOD2/Mn-SOD protein using Rabbit Anti-SOD2/Mn-SOD Polyclonal Antibody (NB100-1992). Load: 15 ugprotein. Block: 1.5% BSA for 30 minutes at RT. Primary Antibody: Rabbit Anti-SOD2/Mn-SOD Polyclonal Antibody (NB100-1992) at 1:1000 for 2 hours at RT. Secondary Antibody: Donkey Anti-Rabbit IgG: HRP for 1 hour at RT.](http://images.novusbio.com/fullsize/SOD2-Mn-SOD-Antibody-Western-Blot-NB100-1992-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: SOD2/Mn-SOD Antibody [NB100-1992] - Analysis using Rabbit Anti-SOD (Mn) Polyclonal Antibody. Tissue: HeLa Cells. Species: Human. Fixation: 2% Formaldehyde for 20 min at RT. Primary Antibody: Rabbit Anti-SOD (Mn) Polyclonal Antibody at 1:120 for 12 hours at 4 degrees C. Secondary Antibody: APC Goat Anti-Rabbit (red) at 1:200 for 120 min at RT. Counterstain: DAPI (blue) nuclear stain at 1:40000 for 120 min at RT. Localization: Mitochondrion matrix. Magnification: 20x. (A) DAPI (blue) nuclear stain. (B) Anti-SOD (Mn) Antibody. (C) Composite.](http://images.novusbio.com/fullsize/SOD2-Mn-SOD-Antibody-Immunocytochemistry-Immunofluorescence-NB100-1992-img0012.jpg)
![Immunohistochemistry: SOD2/Mn-SOD Antibody [NB100-1992] - Immunohistochemistry analysis using Rabbit Anti-SOD2/Mn-SOD Polyclonal Antibody (NB100-1992). Tissue: backskin. Species: Mouse. Fixation: Bouin's Fixative Solution. Primary Antibody: Rabbit Anti-SOD2/Mn-SOD Polyclonal Antibody (NB100-1992) at 1:100 for 1 hour at RT. Secondary Antibody: FITC Goat Anti-Rabbit (green) at 1:50 for 1 hour at RT. Localization: Mitochondrion matrix.](http://images.novusbio.com/fullsize/SOD2-Mn-SOD-Antibody-Immunohistochemistry-NB100-1992-img0017.jpg)
![Immunohistochemistry: SOD2/Mn-SOD Antibody [NB100-1992] - SOD2 mRNA & protein expression. RT-PCR: (A) SOD2 mRNA expression is higher in adults, & highest in the adult parenchyma. (B) No exposure effects on SOD2 mRNA were observed in neonates. (C) Adult SOD2 mRNA was decreased in PFP48. Data are presented as mean+SEM (n=5-7 rats/group, in each compartment), * significantly different compared to neonates in the same compartment, † significantly different compared to airways in the same age, ‡ significantly different compared to FA in the same compartment. Western blotting: (D) Scan of representative SOD2 & actin blots. (E) Neonatal whole lung SOD2 protein expression was unchanged with exposure, & (F) adult whole lung SOD2 protein trended upwards at PFP2, but was statistically insignificant. (G-J) Immunohistochemical localization of SOD2 in lung (n=6 rats/group). SOD2 protein was more abundant in adults compared to neonates, but no exposure specific differences were observed. Scale bar is 50 μm. Image collected & cropped by CiteAb from the following publication (//particleandfibretoxicology.biomedcentral.com/articles/10.1186/1743-8977-10-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1992_rabbit-polyclonal-sod2-mn-sod-antibody-31020241555245.jpg)
![Immunohistochemistry: SOD2/Mn-SOD Antibody [NB100-1992] - SOD2 mRNA & protein expression. RT-PCR: (A) SOD2 mRNA expression is higher in adults, & highest in the adult parenchyma. (B) No exposure effects on SOD2 mRNA were observed in neonates. (C) Adult SOD2 mRNA was decreased in PFP48. Data are presented as mean+SEM (n=5-7 rats/group, in each compartment), * significantly different compared to neonates in the same compartment, † significantly different compared to airways in the same age, ‡ significantly different compared to FA in the same compartment. Western blotting: (D) Scan of representative SOD2 & actin blots. (E) Neonatal whole lung SOD2 protein expression was unchanged with exposure, & (F) adult whole lung SOD2 protein trended upwards at PFP2, but was statistically insignificant. (G-J) Immunohistochemical localization of SOD2 in lung (n=6 rats/group). SOD2 protein was more abundant in adults compared to neonates, but no exposure specific differences were observed. Scale bar is 50 μm. Image collected & cropped by CiteAb from the following publication (//particleandfibretoxicology.biomedcentral.com/articles/10.1186/1743-8977-10-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1992_rabbit-polyclonal-sod2-mn-sod-antibody-3102024168392.jpg)
![Immunohistochemistry: SOD2/Mn-SOD Antibody [NB100-1992] - SOD2 mRNA & protein expression. RT-PCR: (A) SOD2 mRNA expression is higher in adults, & highest in the adult parenchyma. (B) No exposure effects on SOD2 mRNA were observed in neonates. (C) Adult SOD2 mRNA was decreased in PFP48. Data are presented as mean+SEM (n=5-7 rats/group, in each compartment), * significantly different compared to neonates in the same compartment, † significantly different compared to airways in the same age, ‡ significantly different compared to FA in the same compartment. Western blotting: (D) Scan of representative SOD2 & actin blots. (E) Neonatal whole lung SOD2 protein expression was unchanged with exposure, & (F) adult whole lung SOD2 protein trended upwards at PFP2, but was statistically insignificant. (G-J) Immunohistochemical localization of SOD2 in lung (n=6 rats/group). SOD2 protein was more abundant in adults compared to neonates, but no exposure specific differences were observed. Scale bar is 50 μm. Image collected & cropped by CiteAb from the following publication (//particleandfibretoxicology.biomedcentral.com/articles/10.1186/1743-8977-10-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1992_rabbit-polyclonal-sod2-mn-sod-antibody-31020241553748.jpg)
![Western Blot: SOD2/Mn-SOD Antibody [NB100-1992] - CAV-1 preserves mitochondrial respiratory function through regulation of OXPHOS expression.(A) OXPHOS complex subunits were detected through western blotting with appropriate antibodies. CAV-1 treatment significantly restored hypercholesterolemia-associated increased ETC complex I–V proteins levels. (B) Percentage of the OXPHOS complex (I–V) band intensities is presented in the graph. (C) Representative immunoblot displaying levels of CAV-1, CyPA, mitochondrial biogenesis markers, & antioxidant enzymes in the NC, HC, & HCAV-1 groups. (D) Columns represent average values over three independent experiments. The density for the NC group was set at 1; * & † are significantly different for the NC & HC groups, respectively, at P < 0.05. beta -actin was used as a loading control. Values are means ± SD. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0154210), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1992_rabbit-polyclonal-sod2-mn-sod-antibody-3102024155523.jpg)
![Western Blot: SOD2/Mn-SOD Antibody [NB100-1992] - SOD2 mRNA & protein expression. RT-PCR: (A) SOD2 mRNA expression is higher in adults, & highest in the adult parenchyma. (B) No exposure effects on SOD2 mRNA were observed in neonates. (C) Adult SOD2 mRNA was decreased in PFP48. Data are presented as mean+SEM (n=5-7 rats/group, in each compartment), * significantly different compared to neonates in the same compartment, † significantly different compared to airways in the same age, ‡ significantly different compared to FA in the same compartment. Western blotting: (D) Scan of representative SOD2 & actin blots. (E) Neonatal whole lung SOD2 protein expression was unchanged with exposure, & (F) adult whole lung SOD2 protein trended upwards at PFP2, but was statistically insignificant. (G-J) Immunohistochemical localization of SOD2 in lung (n=6 rats/group). SOD2 protein was more abundant in adults compared to neonates, but no exposure specific differences were observed. Scale bar is 50 μm. Image collected & cropped by CiteAb from the following publication (//particleandfibretoxicology.biomedcentral.com/articles/10.1186/1743-8977-10-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1992_rabbit-polyclonal-sod2-mn-sod-antibody-310202415541978.jpg)
![Immunohistochemistry: SOD2/Mn-SOD Antibody [NB100-1992] - SOD2 mRNA & protein expression. RT-PCR: (A) SOD2 mRNA expression is higher in adults, & highest in the adult parenchyma. (B) No exposure effects on SOD2 mRNA were observed in neonates. (C) Adult SOD2 mRNA was decreased in PFP48. Data are presented as mean+SEM (n=5-7 rats/group, in each compartment), * significantly different compared to neonates in the same compartment, † significantly different compared to airways in the same age, ‡ significantly different compared to FA in the same compartment. Western blotting: (D) Scan of representative SOD2 & actin blots. (E) Neonatal whole lung SOD2 protein expression was unchanged with exposure, & (F) adult whole lung SOD2 protein trended upwards at PFP2, but was statistically insignificant. (G-J) Immunohistochemical localization of SOD2 in lung (n=6 rats/group). SOD2 protein was more abundant in adults compared to neonates, but no exposure specific differences were observed. Scale bar is 50 μm. Image collected & cropped by CiteAb from the following publication (//particleandfibretoxicology.biomedcentral.com/articles/10.1186/1743-8977-10-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1992_rabbit-polyclonal-sod2-mn-sod-antibody-310202415535131.jpg)
![Western Blot: SOD2/Mn-SOD Antibody [NB100-1992] - SOD2 mRNA & protein expression. RT-PCR: (A) SOD2 mRNA expression is higher in adults, & highest in the adult parenchyma. (B) No exposure effects on SOD2 mRNA were observed in neonates. (C) Adult SOD2 mRNA was decreased in PFP48. Data are presented as mean+SEM (n=5-7 rats/group, in each compartment), * significantly different compared to neonates in the same compartment, † significantly different compared to airways in the same age, ‡ significantly different compared to FA in the same compartment. Western blotting: (D) Scan of representative SOD2 & actin blots. (E) Neonatal whole lung SOD2 protein expression was unchanged with exposure, & (F) adult whole lung SOD2 protein trended upwards at PFP2, but was statistically insignificant. (G-J) Immunohistochemical localization of SOD2 in lung (n=6 rats/group). SOD2 protein was more abundant in adults compared to neonates, but no exposure specific differences were observed. Scale bar is 50 μm. Image collected & cropped by CiteAb from the following publication (//particleandfibretoxicology.biomedcentral.com/articles/10.1186/1743-8977-10-34), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1992_rabbit-polyclonal-sod2-mn-sod-antibody-3102024165716.jpg)
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody [NB600-336] - Staining of K-562, U266, Daudi and normal T cells with c-Myc antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Immunocytochemistry-Immunofluorescence-NB600-336-img0010.jpg "Immunocytochemistry/Immunofluorescence: c-Myc Antibody [NB600-336] - Staining of K-562, U266, Daudi and normal T cells with c-Myc antibody. ICC/IF image submitted by a verified customer review.")
![Western Blot: c-Myc Antibody [NB600-336] - Detection of c-Myc in HtrA2-Myc Transfectant lysates .](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0012.jpg)
![Western Blot: c-Myc Antibody [NB600-336] - Analysis of c-Myc on Jurkat whole cell extract using NB600-336.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0004.jpg)
![Western Blot: c-Myc Antibody [NB600-336] - Lane 1: control HEK293 cell lysate. Lane 2: CMYC over-expression in HEK293 cell lysate. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0014.jpg)
![Immunohistochemistry: c-Myc Antibody [NB600-336] - Analysis of c-Myc in mouse prostate using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Immunohistochemistry-NB600-336-img0002.jpg)
![Western Blot: c-Myc Antibody [NB600-336] - c-Myc in MOLT-4 cells. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0006.jpg)
![Western Blot: c-Myc Antibody [NB600-336] - Analysis of whole cell lysate (WCL) of Jurkat cells using anti-cMyc antibody (NB600-336) at 1:1000 dilution. HRP conjugated goat anti-rabbit IgG (H+L) cross adsorbed secondary antibody was used with ECL substrate for the detection of c-Myc antibody bound to the blotted protein. This c-Myc antibody detected the c-Myc specific band at its expected position (48-50kDa). The signal below 10 kDa in this blot is potentially the degraded protein and we have not characterized this band.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0013.jpg)
![Western Blot: c-Myc Antibody [NB600-336] - Analysis using the HRP conjugate of NB600-336. Detection of c-Myc in NIH/3T3 cell lysates (30ug and 45ug per lane) using anti-c-Myc antibody. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Western-Blot-NB600-336-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: c-Myc Antibody [NB600-336] - Detection of c-myc Tagged Plakoglobin by Immunofluorescence. Samples: Human microvascular endothelial cells expressing c-myc tagged plakoglobin following transient transfection.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Immunocytochemistry-Immunofluorescence-NB600-336-img0005.jpg)
![Simple Western: c-Myc Antibody [NB600-336] - Lane view shows a specific band for c-Myc in 0.05 mg/ml of Jurkat lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/c-Myc-Antibody-Simple-Western-NB600-336-img0007.jpg)
![Immunohistochemistry: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - ATM [p Ser1981] antibody (10H11.E12) [NB100-306] was tested in mouse spleen using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/ATM-p-Ser1981-Antibody-10H11-E12-Immunohistochemistry-NB100-306-img0005.jpg "Immunohistochemistry: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - ATM [p Ser1981] antibody (10H11.E12) [NB100-306] was tested in mouse spleen using DAB with hematoxylin counterstain.")
![Western Blot: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - Analysis of ATM-kinase, using ATM [p Ser1981] antibody (10H11.E12) [NB100-306]. Sample: Irradiated or peroxidated human fibroblasts. Observed molecular weight 370 kDa. Theoretical molecular weight 351 kDa.](http://images.novusbio.com/fullsize/ATM-p-Ser1981-Antibody-10H11-E12-Western-Blot-NB100-306-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - Human lymphoblastoid cells stained with ATM [p Ser1981] Antibody (10H11.E12). ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/ATM-p-Ser1981-Antibody-10H11-E12-Immunocytochemistry-Immunofluorescence-NB100-306-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: ATM [p Ser1981] Antibody (10H11.E12) [NB100-306] - MCELNs decreased the DNA damage of H9C2 cells after radiation. Western blot images of p-ATM (NB100-306) and ATM (NB100-309) in H9C2 cells after 48 h of culture with indicated treatment. IR (-/+): 0/16 Gy X-ray; MCELNs (-/+): 0/10 ug/mL. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35509278/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nb100-306_mouse-monoclonal-atm-p-ser1981-antibody-10h11-e12-2552023151493.jpg)
![Western Blot: Bcl-2 Antibody [NB100-56098] - Analysis of Bcl-2 in whole cell lysate from Daoy cells. Cells were transfected with (1) scrambled control siRNA or (2) Bcl-2 siRNA. Image from verified customer review.](http://images.novusbio.com/fullsize/Bcl-2-Antibody-Western-Blot-NB100-56098-img0004.jpg "<b>Genetic Strategies Validation. </b>Western Blot: Bcl-2 Antibody [NB100-56098] - Analysis of Bcl-2 in whole cell lysate from Daoy cells. Cells were transfected with (1) scrambled control siRNA or (2) Bcl-2 siRNA. Image from verified customer review.")
![<b>Genetic Strategies Validation. </b>Western Blot: Bcl-2 Antibody [NB100-56098] - EA reduced MPP+-induced dopaminergic neuronal apoptosis by increasing BDNF (brain-derived neurotrophic factor) expression and further Akt phosphorylation in the rat substantia nigra. Eight days after MPP+ administration, our Western blot results (MAB7566) show that MPP+ treatment reduced tyrosine hydroxylase and Bcl-2 expression in the ipsilateral side of the rat substantia nigra (SN), but not in the contralateral side. EA stimulation (50 Hz) enhanced mature BDNF, tyrosine hydroxylase, and Bcl-2 expression in the MPP+-treated ipsilateral side. Image collected and cropped by CiteAb from the following publication (//www.mdpi.com/1422-0067/18/9/1846), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Bcl-2-Antibody-Western-Blot-NB100-56098-img0012.jpg)
![Immunohistochemistry-Paraffin: Bcl-2 Antibody [NB100-56098] - Analysis of a FFPE human breast carcinoma tissue section using 1:1000 dilution of Bcl-2 antibody (NB100-56098) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of BCL2 in the cancer cells with relatively intense signal in their nuclear membranes. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/Bcl-2-Antibody-Immunohistochemistry-Paraffin-NB100-56098-img0011.jpg)
![Western Blot: Bcl-2 Antibody [NB100-56098] - Analysis of Bcl-2 using this antibody at 1:2000, 20 ug/protein was loaded per lane. (1) Human Jurkat T cells. (2) Human RS11 lymphoma cells. (3-6) Human breast cancer cases. Patient sample in lane 5 lacked detectible Bcl-2 expression.](http://images.novusbio.com/fullsize/Bcl-2-Antibody-Western-Blot-NB100-56098-img0005.jpg)
![Western Blot: Bcl-2 Antibody [NB100-56098] - Analysis of Bcl-2 in 293T cell lysate (30ug) using anti-Bcl-2 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/Bcl-2-Antibody-Western-Blot-NB100-56098-img0006.jpg)
![Western Blot: Bcl-2 Antibody [NB100-56098] - Analysis of whole cell lysate (WCL) of Jurkat cells using anti-Bcl-2 antibody (NB100-56098) at 1:1000 dilution. HRP conjugated goat anti-rabbit IgG (H+L) cross adsorbed secondary antibody was used with ECL substrate for the detection of Bcl2 antibody bound to the blotted protein. This Bcl2 antibody detected a specific band at expected molecular weight marker position of Bcl2 protein (26kDa).](http://images.novusbio.com/fullsize/Bcl-2-Antibody-Western-Blot-NB100-56098-img0007.jpg)
![Immunohistochemistry-Paraffin: Bcl-2 Antibody [NB100-56098] - Analysis of a FFPE human breast carcinoma tissue section using 1:1000 dilution of Bcl-2 antibody (NB100-56098) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of BCL2 in the cancer cells with relatively intense signal in their nuclear membranes. The endothelial cells and the stromal cells showed a weak signal while the RBCs were negative for BCL2.](http://images.novusbio.com/fullsize/Bcl-2-Antibody-Immunohistochemistry-Paraffin-NB100-56098-img0010.jpg)